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MaDue to recurrent right ventricular outﬂow tract (RVOT) dysfunction, patients with complex congenital heart disease of
the RVOT traditionally require multiple surgical interventions during their lifetimes. Percutaneous pulmonary valve im-
plantation (PPVI) has been developed as a nonsurgical alternative for the treatment of right ventricular to pulmonary
artery stenosis or pulmonary regurgitation. PPVI has been shown to be a safe and effective procedure in patients with
dysfunctional surgical RVOT conduits. In this population, PPVI has the potential to improve symptoms, functional ca-
pacity, and biventricular hemodynamics. However, limitations to the anatomical substrate and size of the RVOT currently
restrict PPVI eligibility to less than one-quarter of patients with RVOT dysfunction. The current review discusses con-
temporary practices in PPVI, evidence supporting the procedure, and future technologies and developments in the ﬁeld.
(J Am Coll Cardiol 2015;66:2246–55) © 2015 by the American College of Cardiology Foundation.T he incidence of congenital heart disease(CHD) varies between 5 and 8 per 1,000 livebirths (1,2). In adulthood, the estimated prev-
alence is 1 in 150 people (3). Approximately 20% of
newborns with CHD have anomalies in the pulmonary
valve (PV) or right ventricular outﬂow tract (RVOT),
such as tetralogy of Fallot, truncus arteriosus, or pul-
monary atresia (4). For these patients, surgical repair
of the RVOT within the ﬁrst months of life is a life-
saving procedure (5). Surgical strategies for RVOT
reconstruction include patch augmentation, bio-
prosthetic valves, and valved conduits (3,6). Long-
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tient age and the type of tissue or material utilized
(6,7). Ultimately, however, these patients are subject
to progressive RVOT dysfunction due to several
mechanisms, including pulmonary regurgitation
(PR), somatic outgrowth, anastomotic stenosis of the
conduit, valvular stenosis, conduit kinking, sternal
compression, intimal proliferation, conduit calciﬁca-
tion, and aneurysmal degeneration (6,8). Therefore,
repeat surgical interventions are typically required
over a lifetime. Although these procedures have a
low mortality rate, they can be associated with signif-
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AB BR E V I A T I O N S
AND ACRONYM S
CHD = congenital heart disease
LV = left ventricle/ventricular
PA = pulmonary artery
PPVI = percutaneous
pulmonary valve implantation
PR = pulmonary regurgitation
PV = pulmonary valve
RV = right ventricle/ventricular
RVOT = right ventricular
outﬂow tract
SF = stent fracture
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2247(9,10). In this clinical context, percutaneous pulmo-
nary valve implantation (PPVI) has been developed
as a nonsurgical, less invasive alternative for the
treatment of RVOT dysfunction. This paper will re-
view the procedure, devices, indications, outcomes,
complications, and future developments in PPVI.
DEVICES AND TECHNIQUE
Bonhoeffer et al. (11) ﬁrst performed transcatheter PV
implantation in 2000. Improvements to the device
initially used by Bonhoeffer led to the development
of the Melody transcatheter PV (Medtronic Inc.,
Minneapolis, Minnesota) (4,12), which consists of a
bare-metal platinum-iridium stent (CP stent, NuMED,
Inc., Hopkinton, New York) and a manually-sewn
valved segment of bovine jugular vein (Figure 1).
Currently, the Melody valve is available in diameters
of 16 and 18 mm, which can be expanded to 18 or
20 mm, and 18, 20, or 22 mm, respectively. The device
is crimped over a balloon-in-balloon catheter and
delivered through a long 22-F sheathed balloon
catheter (Ensemble Delivery System, Medtronic Inc.).
The balloon-in-balloon technique allows for stepwise
deployment, as the valve can still be repositioned
after the inner balloon is inﬂated. The deliveryFIGURE 1 Melody Transcatheter Pulmonary Valve and Delivery Syst
Melody transcatheter pulmonary valve (top): the valved segment of bo
platinum-iridium stent. Ensemble transcatheter valve delivery system (b
followed by withdrawal of the sheath and exposure of the valve; in the
the outer balloon.system also includes a sleeve over the sheath
to provide hemostasis at the insertion site
(4,13).
The Edwards Sapien Pulmonic trans-
catheter heart valve (Edwards Lifesciences,
Irvine, California) is a trileaﬂet bovine peri-
cardial tissue valve hand-sutured in a
balloon-expandable, radiopaque, stainless-
steel stent (Figure 2). It is available in 23 or
26 mm diameters that require 22- or 24-F
delivery sheaths, respectively. This device
contains a unique proximal sealing cuff
designed to prevent paravalvular leaks. The
valve is implanted using the Retroﬂex-3 de-
livery system (Edwards Lifesciences), which consists
of a guiding catheter and a single-balloon catheter. A
specialized tool is used to manually crimp the valve
over the valvuloplasty balloon (13–15).
Careful pre-procedural assessment is vital for suc-
cessful PPVI and requires collaboration from multi-
modality imaging specialists. Echocardiography is
used for assessment of right ventricular (RV) and left
ventricular (LV) systolic and diastolic function as well
as chamber diameters. Conduit gradients and Doppler
recordings are essential to estimate the severity of
RVOT obstruction and/or PR (12,16,17). Cardiacem
vine jugular vein is hand-sewn to each node of the gold-brazed
ottom): the upper image illustrates the sheath covering the valve,
bottom image, the inner balloon is inﬂated prior to inﬂation of
FIGURE 2 Edwards Sapien Pulmonic Valve and Delivery System
(Top) Edwards Sapien pulmonic valve: trileaﬂet bovine pericardium valve hand-sutured in a stainless-steel stent. (Bottom) Balloon dilation of
the Sapien pulmonic valve mounted on the Retroﬂex delivery system.
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2248magnetic resonance imaging is indicated for evalua-
tion of RV volume, RVOT morphology, and suitability
for PPVI (12,17,18). PPVI is typically performed under
general anesthesia through the femoral, jugular, or
subclavian veins (16,17,19).
Due to variability in coronary anatomy among pa-
tients with complex CHD, approximately 5% of PPVI
candidates are at risk for coronary compression after
valve deployment and RVOT expansion (20). To avoid
this potentially fatal complication (16,21), aortic or
coronary angiography is routinely performed with
simultaneous high-pressure balloon inﬂation in the
valvular landing zone (17,20). PPVI is contraindicated
if coronary ﬂow is impaired by this maneuver (16)
(Figure 3). In addition to evaluating the risk to the
coronaries, balloon pre-dilation of the RVOT is often
necessary to facilitate passage of the delivery system in
calciﬁed or highly stenotic surgical anatomies (22).
Post-deployment balloon dilation, however, can
theoretically lead to PR or cause damage to the valvular
struts. Nevertheless, these ﬁndings have not been
conﬁrmed in clinical studies (22,23), and thus, post-
dilation may be used to further expand the valve and
improve hemodynamics in the presence of a signiﬁcant
residual RVOT gradient (24).EFFICACY OUTCOMES
Overall, trials and registries of PPVI have included
patients with surgical RVOT conduits who develop PR
and/or RVOT stenosis. Regurgitation criteria in pre-
vious studies were moderate or severe PR associated
with signiﬁcant symptoms, RV dysfunction, and/or
RV dilation (12,16,17); stenosis requirements included
either gradient (typically >35 to 40 mm Hg) or RV to
aortic pressure ratio (>0.67) (12,16,17,23). In
dysfunctional surgical RVOT conduits, PPVI has been
shown to normalize the RVOT gradient and resolve
PR immediately after implantation (Table 1). In these
patients, PPVI is also associated with signiﬁcant im-
provements in functional capacity (14,19) and RV
systolic function (18,23). The treatment of PR im-
proves right-sided volume overload, resulting in a
reduction of RV volumes, also known as reverse
remodeling (14,16). Importantly, right-sided reverse
remodeling has been associated with enhanced LV
ﬁlling and higher LV end-diastolic volumes (18).
Moreover, left-sided systolic function is also
improved by PPVI, as observed by an elevation in
LV stroke volume and aortic pressures following the
procedure (18,19). Hemodynamic beneﬁts of PPVI
FIGURE 3 Coronary Compression in Percutaneous Pulmonary Valve Implantation
(A) Coronary angiography reveals compression of the left anterior descending artery with balloon inﬂation in the valvular landing zone.
(B) Aortic angiography demonstrates compression of the left main coronary artery by a deployed percutaneous pulmonary valve.
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2249persist in intermediate and long-term follow-up
(17–19,25,26).
Direct comparisons between surgical intervention
and PPVI have not been performed. PPVI has been
accepted as a therapeutic alternative to RVOT conduit
dysfunction under the premise that it is a safe
and effective procedure (Central Illustration), with the
potential to avoid or delay open-heart surgery and its
associated morbidity. Therefore, it is particularly
important to consider reintervention rates of PPVI, as
transcatheter procedures are not without risk. Overall,
freedom from reintervention after PPVI has been re-
ported above 90%, 80%, and 70% in follow-up periods
of approximately 1, 2, and 4 years, respectively
(17,19,22,25). Recently published data from the U.S.
Investigational Device Exemption trial reported
5-year freedom from reintervention and explant of
76%  4% and 92%  3%, respectively (26). Factors
associated with reinterventions include a high
post-PPVI residual RVOT gradient (17,26) and stent
compression or recoil after valve deployment (22). Pre-
stenting of the RVOT (22,26) and increasing operator
experience (17) have been associated with longer
freedom from reintervention. Given the lack of sufﬁ-
cient long-term data, it is not currently knownwhether
all patients with PPVI will ultimately require repeat
procedures, as occurs in surgical conduits (Table 1).
COMPLICATIONS
Fracture of the percutaneous valve stent frame has
been reported in up to 30% of PPVI cases (27,28). Stent
fractures (SFs) are categorized according to the classi-
ﬁcation by Nordmeyer et al. (27) as follows (Figure 4):type I, no loss of stent integrity; type II, loss of stent
integrity; and type III, separation or embolization of
the fractured segment. Although a common compli-
cation, the majority of SFs are nonclinically relevant
type I fractures, which are usually diagnosed by rou-
tine radiography or ﬂuoroscopy (22,28). Nevertheless,
RVOT obstruction secondary to SF remains the most
common cause for reintervention after PPVI (17,19).
Type I fractures are typically managed conservatively
and followed regularly, as they can progress to more
advanced fractures (22). Type II and III fractures can be
successfully treated with valve-in-valve procedures,
although type III SFsmay require surgicalmanagement
in the case of distal strut embolization (16,17,29).
Risk factors associated with percutaneous PV
SF include: younger age; higher pre- and post-
procedural RVOT gradient; smaller angiographic con-
duit diameter; stent recoil or compression after
deployment; and valve position directly under the
sternum (22,27,30). Deployment of 1 or more balloon-
expandable stents in the RVOT prior to PPVI, a tech-
nique known as pre-stenting, has been shown to
decrease the incidence of SF (22) and prolong freedom
from fracture-related reinterventions (28). Although
pre-stenting increases ﬂuoroscopy time (28), the
additional bare-metal stent also serves as a landmark
and landing zone for valve placement (15,28,31). PPVI
is usually performed in the same procedure, but can be
done in a staged intervention 2 to 3 months after pre-
stenting to allow for stent endothelial ingrowth (31).
The risk of infective endocarditis following PPVI has
been estimated at 2.4% per patient-year (32). More
than one-half of cases do not directly involve the
implanted PV, andmost respond to antibiotics without
TABLE 1 Summary of Clinical Studies in Percutaneous Pulmonary Valve Implantation
First Author, Year (Ref. #) Country Time Period N
Age
(yrs)
Weight
(kg)
Follow-Up
(Months) Valve
Procedure
Success* Reinterventions† PR‡
SF
(SF-r)†
RVOT Tear
or Rupture†
Improved Findings
in Addition to RVOT
Stenosis and PR
Armstrong et al., 2014 (36) United States July 2010 to
July 2012
101 19.9 59.4 12 Melody 98% 2 surgical
0 transcatheter
0 7 (1) 6 NYHA functional class,
tricuspid regurgitation
Butera et al., 2013 (23) Italy October 2007 to
October 2010
63 24 60 30 Melody 93.6% 3 surgical
2 transcatheter
1 10 (2) 1 RV/Ao, RVEDV, RVEF,
RVESV, RVSP
Cheatham et al., 2015 (26) United States January 2007 to
January 2010
150 19 NA 54 Melody NA 8 surgical
28 transcatheter
1 50 (25) 1 Exercise capacity, NYHA
functional class
Eicken et al., 2011 (16) Germany December 2006 to
July 2010
102 21.5 63 11.7 Melody NA 2 surgical
9 transcatheter
NA 5 (3) 0 RV/Ao, RVEDV
Haas et al., 2013 (15) Germany NA 22 21.7 56.5 5.7 SAPIEN 95.5% 1 transcatheter 0 NA NA NYHA functional class,
PA pressures, RVSP
Kenny et al., 2011 (14) United States,
United
Kingdom
April 2008 to
May 2010
36 30.3 73.4 6 SAPIEN 97.1% 3 surgical
1 transcatheter
1 0 NA NYHA functional class,
PA pressures, RV/Ao,
RVEDV, RVSP
Khambadkone et al., 2005 (18) France, United
Kingdom
January 2000 to
September 2004
59 16 56 9.8 Melody 98.3% 8 surgical
5 transcatheter
1 7 (2) 2 Exercise capacity, LVEDV,
LVSV, NYHA functional
class, RVEDV
Lurz et al., 2008 (17) France, United
Kingdom
September 2000 to
February 2007
155 21.2 NA 28.4 Melody NA 23 surgical
22 transcatheter
2 32 (9) 4 PA pressures, RVSP
McElhinney et al., 2010 (19) United States January 2007 to
August 2009
136 19 NA NA Melody 99.1% 1 surgical
10 transcatheter
0 25 (9) 2 Ao pressure, NYHA
functional class, RV/Ao,
RVEDV, RV mass
*Deﬁned by Armstrong et al. (36) as the percentage of subjects with a transcatheter pulmonary valve placed in the desired location, with no more than mild PR, an RV-PA peak-to-peak gradient <35 mm Hg by angiography, and freedom from explantation at 24 h
post-implantation. †Absolute number of patients with complications during follow-up. ‡Absolute number of patients with moderate or severe pulmonary regurgitation on latest follow-up.
Ao ¼ aortic; LVEDV ¼ left ventricular end-diastolic volume; LVSV ¼ left ventricular stroke volume; NA ¼ not available; NYHA ¼ New York Heart Association; PA ¼ pulmonary artery; PR ¼ pulmonary regurgitation; RV ¼ right ventricle; RV/Ao ¼ right ventricular to
aortic pressure ratio; RVEDV ¼ right ventricular end-diastolic volume; RVEF ¼ right ventricular ejection fraction; RVESV ¼ right ventricular end-systolic volume; RVOT ¼ right ventricular outﬂow tract; RVSP ¼ right ventricular systolic pressure; SF ¼ absolute number of
stent fractures; SF-r ¼ stent fractures requiring reintervention
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CENTRAL ILLUSTRATION PPVI: Overview of Contemporary Practices
and the Evolving Future
Percutaneous Pulmonary Valve Implantation (PPVI) as a Nonsurgical 
PPVI candidate
Either:
Moderate/severe pulmonary regurgitation (PR), or
moderate/severe right ventricular to pulmonary artery stenosis
Plus, either:
Surgical RVOT conduit, or
or
or
PPVI procedure
Assessment of coronary compression risk;
pre-stenting of the RVOT;
balloon pre-dilation of the RVOT
Assessment to determine suitability for PPVI
Echocardiography; magnetic resonance imaging;
conduit gradient; conduit diameters; RVOT morphology
Positive Results
Improved symptoms
 Increased functional capacity
Normalized RVOT gradient
Resolved PR
Reverse remodeling
Freedom from reintervention
and explant (>90% at 1 yr)
Reported complications
Risk of coronary compression 
during procedure
Stent fracture 
Infective endocarditis
RVOT tear or rupture 
Need for reintervention
Ansari, M.M. et al. J Am Coll Cardiol. 2015; 66(20):2246–55.
Candidates for PPVI include patients with moderate to severe PR or right ventricle-to-
pulmonary artery stenosis with a previous surgical RVOT conduit. Future techniques and
devices have the potential to expand routine PPVI eligibility to patients with native
RVOTs, as well as those with RVOT diameters that are either smaller or larger than
currently available devices. Pre-procedural assessment includes detailed imaging of the
RVOT to determine gradients, diameters, and morphology. Prior to valvular deployment,
the risk of coronary compression is evaluated with aortic/coronary angiography and
simultaneous high-pressure balloon inﬂation in the RVOT. Although fracture of the
valvular stent frame can lead to recurrent obstruction, approximately three-quarters of
patients have freedom from reintervention at 5 years. PPVI improves clinical symptoms
and hemodynamic parameters associated with RVOT dysfunction, with the potential
beneﬁt to avoid or delay open heart surgery and its associated morbidity. PR ¼ pulmonary
regurgitation; PPVI ¼ percutaneous pulmonary valve implantation; RVOT ¼ right ven-
tricular outﬂow tract.
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2251the need for reintervention (32). However, infective
endocarditis can also lead to valve explantation (16,17),
need for a second PPVI (32), or even sepsis-related
mortality (32). A high residual RVOT gradient, the
resulting turbulence, and in situ thrombosis have been
implicated in the pathophysiology of post-PPVI endo-
carditis (33). Noncompliance with recommended
antibiotic prophylaxis is also commonly reported in
transcatheter PV endocarditis (18,23). Mortality asso-
ciated with PPVI is rare and is most often related to
comorbidities, rather than the procedure itself (17,23).
Pre- and post-deployment balloon dilations have
the potential to cause a tear or rupture in the RVOT.
Risk factors include heavy RVOT calciﬁcation and a
homograft substrate (34). Although the incidence of
such complications has been reported to be as high as
9% (34), most cases are not associated with hemody-
namic compromise and can be successfully managed
with a covered stent (35). In the Melody valve post-
approval study, 6 of 101 patients experienced a
conﬁned conduit tear, all of which resolved with
covered stent placement (36). Rarely, surgical conduit
replacement may be required after a rupture (22).
Other complications that can potentially demand ur-
gent surgical conversion are rare, and include valve
migration or embolization (14,23), pulmonary artery
(PA) occlusion or rupture (28), and coronary artery
compression (37).
CURRENT GUIDELINES, INDICATIONS,
AND CONTRAINDICATIONS
On the basis of much of the aforementioned evidence,
the 2010 guidelines from the European Society of
Cardiology and Association for European Pediatric
Cardiology recommend PPVI with the same
indications as surgical PV replacement (38). In symp-
tomatic patients, these guidelines endorse interven-
tion when the RV systolic pressure is above 60 mm Hg
(tricuspid regurgitation velocity >3.5 m/s) and/or
when there is moderate or severe PR. PPVI is also
indicated in asymptomatic patients with severe RVOT
stenosis and/or severe PR in the presence of decreased
exercise capacity, progressive RV dilation, progressive
RV systolic dysfunction, progressive tricuspid regur-
gitation, RV systolic pressure >80 mm Hg, or sus-
tained ventricular or atrial arrhythmias (38).
A 2011 scientiﬁc statement from the American
Heart Association, American Academy of Pediatrics,
and Society of Cardiovascular Angiography and In-
terventions assigned a Class IIa recommendation
(Level of Evidence: B) for PPVI in patients with a RV-
to-PA conduit in the presence of moderate to severe
pulmonary regurgitation or stenosis, provided that
FIGURE 4 SF Complications in Percutaneous Pulmonary Valve Implantation
(A) Chest radiography demonstrates percutaneous pulmonary valve stent fractures (SFs) without compromising stent integrity (type I SF).
(B) Chest radiography illustrates a type II SF, characterized by architectural distortion and loss of stent integrity, without separation of the
fractured segment.
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2252clinicians adhere to the inclusion/exclusion criteria
for each available valve (39). PPVI is currently not
recommended in native or patch-augmented RVOTs
and in conduits <16 mm in diameter. Absolute con-
traindications include active infection, occluded
central veins, and coronary compression observed
with RVOT balloon dilation (38,39).
FUTURE DEVELOPMENTS
OFF-LABEL USE. Currently, indications for PPVI are
limited to dysfunctional surgical RVOT conduits
(including left heart disease with prior Ross proce-
dure), with dilated diameters between 18 to 22 mm
and 23 to 26 mm for the Melody and Sapien valves,
respectively (13,14,40). However, it is estimated
that <20% of patients with CHD and RVOT dysfunc-
tion meet these restricted criteria (31,41). The ma-
jority of patients with the potential to beneﬁt from
PPVI have an off-label indication for the procedure,
including native or large patch-augmented RVOTs,
bioprosthetic valves, or small-diameter conduits
(<16 mm) (Central Illustration).
Boshoff et al. (31) reported 23 off-label cases of
PPVI, including 8 patients with conduit-free patch-
augmented RVOTs, 2 native PV stenosis, and 13 un-
dersized conduits. The peak RVOT gradient was
signiﬁcantly decreased, and no more than mild PR
was observed in a mean follow-up of 1.2 years. Repeat
interventions due to restenosis were required in 2
patients. There were no vascular complications, SF,
or valve migration during follow-up. Meadows et al.
(42) found resolution of the peak RV-to-PA gradientfollowing successful PPVI in 31 patients with native or
nonconduit dysfunctional RVOTs. Similarly encour-
aging results have been observed in transcatheter
valve-in-valve implantation within failed biopro-
sthetic valves. Gillespie et al. (43) reported 104 cases
of PPVI in bioprosthetic valves. At 1-year median
follow-up, restenosis was observed in 4 patients,
whereas none had more than mild PR. Two SFs were
identiﬁed during follow-up, neither of which required
RVOT reintervention. Overall, freedom from reinter-
vention was >90% at 2 years, and there was no
procedure-related mortality.
The use of approved devices for off-label in-
dications has been associated with an increased
incidence of complications, as compared with stan-
dard indications (44). Furthermore, there are liability
and ethical concerns with off-label device use (31).
However, there are instances where devices and
procedures are clinically indicated on the basis of the
published medical data and/or standards of practice
in the medical community, but remain off-label ac-
cording to regulatory agencies (31,44). In such cases,
patients can be deprived of effective treatment stra-
tegies if device use is strictly restricted to standard
“on-label” indications. Developments in PPVI tech-
nology and larger clinical studies in patients with
native, undersized, or nonconduit RVOTs will likely
expand the “on-label” indications for PPVI in the
near future. Meanwhile, physicians considering an
off-label procedure must evaluate clinical appropri-
ateness on a case-by-case basis. This decision re-
quires a careful assessment of patient preferences,
guided by an informed decision-making process,
FIGURE 5 The Native Outﬂow Tract Transcatheter Pulmonary Valve
This valve (Medtronic Inc., Minneapolis, Minnesota) has an hourglass contour,
with larger diameters in the proximal and distal ends. This self-expandable,
porcine pericardial valve has the potential to expand percutaneous pulmonary
valve implantation to patients with large-diameter outﬂow tracts.
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2253as well as a review of safety and efﬁcacy outcomes
data published in similar patients.
TECHNIQUES AND DEVICES
A number of innovative strategies have been studied
in an effort to expand the population eligible for
PPVI, particularly in patients with large RVOT di-
ameters. If effective in oversized RVOTs, these new
techniques and devices have the potential to expand
PPVI indications to more than 50% of dysfunctional
RVOTs (41). In 2010, Schievano et al. (45) reported the
successful deployment of a transcatheter self-
expanding PV. This device, later called the Native
Outﬂow Tract device (Medtronic, Inc.), has completed
enrollment in an ongoing Investigational Device
Exemption trial. It has an hourglass contour
(Figure 5), with larger diameters at the proximal
and distal ends and a smaller diameter in the center,
where a porcine pericardial valve sits. The self-
expanding nature of the nitinol stent has the poten-
tial, in theory, to improve valvular stability in
heterogeneous RVOT morphologies (46).
The Venus P Valve (Venus Medtech, Shanghai,
China) is another novel self-expanding percutaneous
pulmonary device. It is composed of a trileaﬂet
porcine pericardial valve mounted on a covered
nitinol stent frame. It is manually crimped onto a
delivery system that ranges from 14- to 22-F,
depending on valvular size, which varies from 20 to
32 mm. Small case series have demonstrated short-
term safety and efﬁcacy of PPVI with the Venus P
Valve (47,48). Given the applicability of this device in
large patch-augmented RVOTs, it may play an
important role in the future of PPVI if favorable re-
sults are conﬁrmed in clinical trials. Similarly, the
Sapien XT (Edwards Lifesciences) 29-mm valve may
also become an alternative for large-diameter RVOTs,
although this valve has not yet been sufﬁciently
studied in the pulmonary position. Percutaneous
devices for RVOT size reduction have been success-
fully implanted in sheep with enlarged RVOTs
(49,50), but remain to be tested in humans. Other
advanced techniques have been successfully per-
formed in sporadic cases of patients with highly-
complex RVOT anatomy, including Melody valve
implantation in bilateral PA (51), and a PA “jailing”
technique, in which overlapping uncovered bare-
metal stents were deployed from a PA branch down
to the RVOT as an anchor for PPVI (52).
The patient population suitable for PPVI is
also somewhat limited by the large-proﬁle sheaths
required for the procedure (22- to 24-F). Berman
et al. (35) reported good procedural hemodynamicoutcomes in 25 patients <30 kg (median age 8 years;
median weight 21.4 kg) who underwent PPVI. Inability
to advance the delivery sheath prevented valve im-
plantation in 1 patient. In addition, another patient
developed an abdominal hematoma secondary to
trauma from crossing the delivery system through the
femoral-caval junction. Low-proﬁle devices are
currently being developed, and will likely make the
procedure safer in younger pediatric patients.
In conformity with a heart team approach for
structural heart disease interventions (53), hybrid
procedures with mutual collaboration from cardiac
surgery and interventional cardiology will likely
shape the future of PPVI. A hybrid approach allows
for minimally invasive surgical techniques (54,55)
and permits structural heart disease intervention-
alists to collaborate in planning the most favorable
surgical RVOT substrate, in anticipation of potential
future transcatheter procedures.
TIMING OF INTERVENTION
Prior to the development of PPVI, patient and/or
physician concerns for repeated surgical procedures
had the potential to delay interventions for RVOT
dysfunction, often compromising ventricular recovery
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2254and placing patients at an increased risk for sudden
cardiac death (4,56,57). Borik et al. (58) recently
demonstrated that younger patients with RVOT
dysfunction derive the most beneﬁt from PPVI. The
authors found an incremental improvement in LV
ejection fraction, oxygen consumption, and RV end-
diastolic volume with younger age, concluding that
early PPVI is associated with better hemodynamic re-
sults. Strategies for safer and more durable trans-
catheter PVs will likely shift medical decisions toward
earlier percutaneous valve implantation in the future
(34,59).
CONCLUSIONS
PPVI has been consolidated as a safe and effec-
tive nonsurgical therapeutic alternative for RVOT
dysfunction. In patients with stenotic or regurgitant
surgical RVOT conduits, PPVI has a high proce-
dural success rate, with immediate and durableresolution of RV-to-PA gradient as well as a very
low incidence of post-procedure PR (Central
Illustration). Less than 25% of patients who un-
dergo PPVI will require repeat interventions in a
5-year period, most commonly secondary to a fracture
in the percutaneous valve stent frame. Future
developments in the ﬁeld aim to reduce the incidence
of complications, improve freedom from reinter-
vention rates, and, most importantly, expand the
population eligible for this elegant procedure. Clinical
studies in off-label populations, innovative devices,
and new techniques will likely expand the indications
to native RVOTs, small-diameter conduits, and over-
sized patched RVOTs.
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